Grabarczyk Piotr, Brojer Ewa, Windyga Jerzy, łopaciuk Stanisław, Klukowska Anna, Mikulska Maria
Instytut Hematologii i Transfuzjologii w Warszawie, Zakład Immunologii Hematologicznej i Transfuzjologicznej, Warszawa.
Przegl Epidemiol. 2006;60(3):581-8.
Viruses GBV-C/HGV and TTV were identified in patients with hepatitis of unknown etiology. Aim of our study was to assess the frequency of infection markers of these viruses in blood donors and haemophilia patients treated with virucidaly activated and non inactivated blood products. Material and methods. TTV DNA (by PCR using primers to coding ORFI and non-coding region NC) and GBV-C/HGV (RNA by RT-PCR and anti-E2 by EIA) were tested in blood donors (200 for TTV and 219 for GBV-C/HGV), 122 haemophilia patients treated in the past with non inactivated blood products and in 20 haemophilia children treated exclusively with inactivated clotting preparations. Results RNA GBV-C/HGV were identified in 3,2%; 23,7% and in 0%, respectively blood donors, adult and children haemophilia patients. Antibody anti-E2 were found in 23,6%; 37% i 25% of studied groups respectively. DNA TTV was detected most frequently by NC than ORF1 primers: in 78% vs.10% of blood donors, 100% vs 43,5% of adult haemophilia patients and in 95% vs. 15% young haemophiliacs. Conclusions Haemophilia patients were at risk of GBV-C/HGV and TTV infection. Following implementation of viral inactivation methods in the process of clotting factor concentrates production, the risk for GBV-C/HGV transmission was significantly reduced and in less extant for TTV.
